Management of immune thrombocytopenia during COVID-19 pandemic

Introduction . The COVID-19 pandemic has challenged health professionals and patients suffering from haematological diseases with embarrassed diagnosis, treatment, surveillance, social distancing other constraints. Aim — addressing therapy for immune thrombocytopenia (ITP) during the in light of own experience, as well national international professional medical community guidelines. Main findings A standard choice COVID-19-negative ITP are conventional, e.g., glucocorticosteroid (GCS) intravenous immunoglobulin therapies. An early transfer to thrombopoietin receptor agonists (rTPO) appears optimal reducing infection risk GCS withdrawal significantly improving stable remission rate without supportive treatment. Combined ITP–COVID-19 should consider a prednisolone treatment 20 mg/day, provided an absent active bleeding. dose may increase 1 mg/kg/day no response after 3–5 days. admitted start weight‐based LMWH thromboprophylaxis upon attaining platelet count ≥ 30 × 109 /L. Chronic carry on usual SARS-CoV-2 preventive measures. We exemplify three contrasting clinical cases COVID-19-comorbid discuss differential diagnosis therapy. Two received GCSs rTPO (romiplostim, eltrombopag), while alone third case. All showed good biological response. Issues vaccination discussed.